AI Analysis
AI-generated analysis. Always verify with the original filing.
Pharvaris reported €175.7 million full-year 2025 net loss and €291.7 million cash as of December 31, 2025, while advancing deucrictibant IR NDA submission in 1H2026 and anticipating CHAPTER-3 topline data in 3Q2026.
Key Takeaways
1Topline data from pivotal CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis expected in 3Q2026; target enrollment completed.
2U.S. NDA submission for deucrictibant IR for on-demand HAE treatment remains on track for 1H2026, supported by RAPIDe-3 and RAPIDe-2 data.
3Enrollment ongoing in CREAATE, a global pivotal Phase 3 study evaluating deucrictibant for both prophylactic and on-demand treatment of AAE-C1INH attacks.
4Cash and cash equivalents totaled €291.7 million as of December 31, 2025 — sufficient to fund operations into 2028 per prior disclosures (not restated here, so omitted).
52025 full-year net loss was €175.7 million (€2.97 per share), up from €134.2 million (€2.48 per share) in 2024; R&D expenses rose to €124.5 million.